目的：探讨多西紫杉醇和顺铂的联合治疗方案对晚期非小细胞肺癌患者的治疗效果、毒副作用及预后。方法：选取88例晚期非小细胞肺癌患者，将其根据随机数字表法分为治疗组和对照。治疗组采用多西紫杉醇联合顺铂的综合治疗方案，对照组仅应用顺铂或姑息对症治疗。结果：治疗组治疗有效率为45．5％（20/44），显著高于对照组的22．7％（10/44），差异具有统计学意义（P＜0．05）。治疗组患者平均生存期为（12．5±2．1）月，一年生存率为47．7％，与对照组患者（8．3±1．9、27．3％）相比差异显著（ P＜0．05）。对两组患者治疗后毒副反应发生进行比较，差异无统计学意义（ P＞0．05）。结论：紫杉醇和顺铂的联合治疗方案治疗晚期非小细胞肺癌疗效显著，患者生存期延长，可作为晚期非小细胞肺癌治疗的一线标准治疗方案优先选择。%Objective:To investigate the side effects and prognosis of paclitaxel and cisplatin combina-tion therapy for advanced non-small cell lung cancer .Method:88 elderly patients with advanced non-small cell lung cancer were divided into treatment group and control group according to the random number table . The treatment group received paclitaxel plus cisplatin comprehensive treatment program , the control group used cisplatin treatment or palliative symptomatic treatment .Results:The effective rate of treatment group was 45.5%(20/44), significantly higher than the control 22.7%(10/44), the difference had statistically significant (P<0.05).In the treatment group, the average survival time was (12.5 ±2.1) months, one year survival rate was 47.7%, compared with the control group of patients (8.3 ±1.9,27.3%), there were signif-icant difference (P<0.05).The occurrence of toxicity of two groups had no statistically significant (P>0. 05).Conclusion:In the treatment of advanced non-small cell lung cancer, paclitaxel and cisplatin combi-nation therapy has good effects , can significantly prolong survival time of patients , as the treatment of ad-vanced non-small cell lung cancer first-line standard treatment preference .
展开▼
